Hongfu Cai

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 8

Top Topics

Radiation Therapy

Small Cell Lung Cancer

Systematic Review

Top Venues

Therapeutic advances in medical oncology

Cancer management and research

Journal of clinical pharmacy and therapeutics

Journal of comparative effectiveness research

This page only lists publications with an associated author ORCID identifier.

Publications

Xueqiong Cao, Mingming Zhang, Na Li, Bin Zheng, Maobai Liu, Xiaobing Song, Hongfu Cai
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis. Therapeutic advances in medical oncology 15 (2023)
Gaofeng Zhu, Hongfu Cai, Zhiwei Zheng
Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis. Therapeutic advances in medical oncology 15 (2023)
Xueqiong Cao, Hongfu Cai, Na Li, Bin Zheng, Zhiwei Zheng, Maobai Liu
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis. Therapeutic advances in medical oncology 14 (2022)
Liu Yang, Zhiwei Zheng, Na Li, Bin Zheng, Maobai Liu, Hongfu Cai
Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: A systematic review and meta-analysis. Journal of clinical pharmacy and therapeutics (2022)
Liu Yang, Maobai Liu, Xueqiong Cao, Na Li, Bin Zheng, Jianhao Deng, Hongfu Cai
Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis. Therapeutic advances in medical oncology 14 (2022)
Liu Yang, Xueqiong Cao, Na Li, Bin Zheng, Maobai Liu, Hongfu Cai
Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma. Therapeutic advances in medical oncology 14 (2022)
Longfeng Zhang, Na Li, Maobai Liu, Bin Zheng, Zhijuan Wu, Hongfu Cai
Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer. Cancer management and research 13 (2021)
Longfeng Zhang, Xiaofang Zeng, Hongfu Cai, Na Li, Maobai Liu, Lingling Qiu, Bin Zheng
Cost-effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer. Journal of comparative effectiveness research 9 (18) (2020)